NCT07477366 2026-03-17
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
ImmunityBio, Inc.
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT07137481 2026-03-04
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07365306 2026-01-26
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07259122 2025-12-02
ZBR in WM
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07034508 2025-06-24
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT06973811 2025-05-20
ZR-MTX
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT06557330 2025-01-06
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
Fox Chase Cancer Center
Phase 2 Not yet recruiting
NCT06516978 2024-07-24
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06441097 2024-06-04
Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Ruijin Hospital
Phase 2 Not yet recruiting
NCT05280626 2022-03-15
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Not yet recruiting
NCT04913103 2021-06-04
CLSGMCLPOLA
Czech Lymphoma Study Group
Phase 2 Not yet recruiting